The potential reassessment of cannabinoids, particularly at the federal level, is generating considerable anticipation within the industry. A shift away from Schedule I status, often viewed as outdated website and hindering innovation, could unlock significant possibilities for companies. Reduced regulatory burdens, alongside greater access to bank